Predicting Intracerebral Hemorrhage Outcomes With Peak Perihemorrhagic Edema
Further research may be necessary to better understand the pathophysiologic mechanisms involved in perihemorrhagic edema evolution and ICH.
Further research may be necessary to better understand the pathophysiologic mechanisms involved in perihemorrhagic edema evolution and ICH.
For patients with CKD and atrial fibrillation, anticoagulants are linked with an increased risk of ischemic stroke.
Outcomes in intracerebral hemorrhage are less severe in patients with prior NOAC use.
Results from a secondary analysis of the ENCHANTED trial add to a pile of weak data that likely will not affect clinical practice.
Surprisingly, no evidence was found to suggest that patients with these markers benefit from intensive blood pressure reduction.
Intensive antiplatelet therapy appears to reduce risk of recurrence immediately after stroke, but may pose risks further out.
Resumption of oral anticoagulants after intracerebral hemorrhage was found to improve outcomes at 1 year.
The investigators reported no difference in 3-month mortality rates across all 5 studies included in the meta-analysis.
Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.
As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.